Roche’s attempt to muscle in on paroxysmal nocturnal hemoglobinuria (PNH) is on track. The subcutaneous anti-C5 recycling antibody crovalimab improved outcomes in a Chinese phase 3 trial, giving the ...
(RTTNews) - AstraZeneca reported that Soliris has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis in paediatric patients who are anti-acetylcholine ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its planned Stelara biosim rollout in 2025. But thanks to a new FDA approval, the ...
Novartis has its eye on the market held by a pair of AstraZeneca's rare disease gems. The latest data showing that the Swiss drugmakers' iptacopan increases hemoglobin levels in a disease called ...
Apellis Pharmaceuticals (APLS) reported positive phase 3 results of pegcetacoplan (APL-2) in PNH patients. Pegcetacoplan, the company's C3 inhibitor, managed to beat Alexion Pharmaceuticals’ (ALXN) ...
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its medicine crovalimab met the main goal of a phase 3 study and helped achieve disease control in patients with paroxysmal nocturnal hemoglobinuria (PNH) who ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results